Research programme: diarrhoea therapies - BioFocus/OneWorld Health
Latest Information Update: 14 Oct 2010
At a glance
- Originator BioFocus DPI; Institute for OneWorld Health
- Developer Institute for OneWorld Health
- Class Heterocyclic compounds
- Mechanism of Action Chloride channel antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Diarrhoea